Brian Goff, Agios CEO

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Agios and Al­ny­lam have agreed on an ex­clu­sive glob­al li­cens­ing deal worth $147.5 mil­lion for Agios to take over the de­vel­op­ment and com­mer­cial­iza­tion of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.